WK369
WK369 is a novel BCL6 small molecule inhibitor, which exhibits excellent anti-ovarian cancer bioactivity, induces cell cycle arrest and causes apoptosis. WK369 can directly bind to the BCL6-BTB domain and block the interaction between BCL6 and SMRT, leading to the reactivation of p53, ATR and CDKN1A[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; BCL6
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/wk369.html
Purity
99.89
Solubility
DMSO : 100 mg/mL (ultrasonic; warming)
Smiles
O=C(C=C1)OC2=C1C=C(NC3=NC(N4C[C@H](C)N[C@H](C)C4)=NC=C3F)C=C2
Molecular Formula
C19H20FN5O2
Molecular Weight
369.39
References & Citations
[1]Wu M, et al. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer. Int J Biol Sci. 2024 Jan 1;20 (2) :486-501.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
125634 100 µL
DARC (Duffy Antigen/Chemokine Receptor, Fy Glycoprotein, GpFy, Glycoprotein D, Plasmodium Vivax Receptor, CD234, FY, GPD) (Not for Export EU)
Sign In for Pricing
View Details 